While humans can regularly replace certain cells, like those in our blood and gut, we cannot naturally regrow most other ...

While the complete response letter derails a near-term clearance, one analyst described the rejection as more of “a speed ...

Just as firefly season lights up Pennsylvania fields, a new study led by Bucknell researchers is shining a light on an ...

T he fashion industry loves a famous name. Fresh crops of celebrity kids-turned-runway-habitués spring up in tandem with the fashion seasons, some lucky enough to have more staying power than others.

When a nonprofit meets the right expert at the right time, amazing things can happen. That’s exactly what unfolded when Bloom featured the powerful story of a partnership ...

Metagenomi Inc. (NASDAQ: MGX) is one of the best young stocks to buy and hold for 5 years. In mid-May, Metagenomi announced ...

Ambitious projects aim to put dire wolves, woolly mammoths and passenger pigeons back into our ecosystems. But with so many ...

Medically reviewed by Jeffrey S. Lander, MD ATTR-CM is an acronym for the medical condition called transthyretin amyloid cardiomyopathy. There are two causes of ATTR-CM, an inherited gene mutation and ...

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer.

The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...